David Helfgott

3.8k total citations · 1 hit paper
23 papers, 3.0k citations indexed

About

David Helfgott is a scholar working on Epidemiology, Immunology and Infectious Diseases. According to data from OpenAlex, David Helfgott has authored 23 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 11 papers in Immunology and 9 papers in Infectious Diseases. Recurrent topics in David Helfgott's work include Immune Response and Inflammation (6 papers), Antifungal resistance and susceptibility (5 papers) and Fungal Infections and Studies (5 papers). David Helfgott is often cited by papers focused on Immune Response and Inflammation (6 papers), Antifungal resistance and susceptibility (5 papers) and Fungal Infections and Studies (5 papers). David Helfgott collaborates with scholars based in United States, Germany and Netherlands. David Helfgott's co-authors include L T May, Pravinkumar B. Sehgal, Oliver A. Cornely, Thomas J. Walsh, John R. Perfect, Johan Maertens, Jerzy Hołowiecki, Mario Petrini, Andrew J. Ullmann and Dick Stockelberg and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

David Helfgott

23 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

2007 1.3k citations Oliver A. Cornely, Johan Maertens et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Helfgott United States	15	1.5k	1.4k	757	674	333	23	3.0k
J Tollemar Sweden	30	1.7k 1.1×	1.7k 1.2×	463 0.6×	215 0.3×	204 0.6×	87	3.1k
C. V. Paya United States	37	2.7k 1.8×	1.2k 0.9×	1.1k 1.5×	1.2k 1.8×	820 2.5×	69	5.1k
Howard S. Jaffe United States	30	1.4k 0.9×	854 0.6×	716 0.9×	781 1.2×	313 0.9×	39	3.4k
Charles H. Kirkpatrick United States	34	1.4k 0.9×	1.3k 0.9×	248 0.3×	1.6k 2.3×	542 1.6×	150	4.1k
Koichi Uyemura United States	32	1.6k 1.0×	1.1k 0.7×	610 0.8×	2.9k 4.3×	588 1.8×	48	4.9k
Soon‐Pal Suh South Korea	28	1.4k 0.9×	1.6k 1.1×	168 0.2×	281 0.4×	625 1.9×	177	3.0k
Michael K. Mansour United States	30	1.5k 1.0×	1.7k 1.2×	265 0.4×	787 1.2×	1.1k 3.3×	100	3.6k
Laurent Alric France	44	2.7k 1.7×	1.2k 0.8×	297 0.4×	399 0.6×	489 1.5×	182	5.9k
Kathryn E. Tanaka United States	24	1.8k 1.2×	1.4k 1.0×	440 0.6×	1.0k 1.5×	894 2.7×	41	3.7k
Harrys A. Torres United States	35	2.4k 1.5×	1.7k 1.2×	586 0.8×	115 0.2×	198 0.6×	114	3.6k

Countries citing papers authored by David Helfgott

Since Specialization

Citations

This map shows the geographic impact of David Helfgott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Helfgott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Helfgott more than expected).

Fields of papers citing papers by David Helfgott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Helfgott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Helfgott. The network helps show where David Helfgott may publish in the future.

Co-authorship network of co-authors of David Helfgott

This figure shows the co-authorship network connecting the top 25 collaborators of David Helfgott. A scholar is included among the top collaborators of David Helfgott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Helfgott. David Helfgott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Helfgott, David, Sabrina Racine‐Brzostek, Zhen Zhao, et al.. (2022). Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia & lymphoma. 64(3). 662–670. 3 indexed citations

Cornely, Oliver A., Rafael F. Duarte, Shariq Haider, et al.. (2015). Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. Journal of Antimicrobial Chemotherapy. 71(3). 718–726. 130 indexed citations

Duarte, Rafael F., Javier López‐Jiménez, Oliver A. Cornely, et al.. (2014). Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia. Antimicrobial Agents and Chemotherapy. 58(10). 5758–5765. 81 indexed citations

Satlin, Michael J., David P. Calfee, Liang Chen, et al.. (2012). Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leukemia & lymphoma. 54(4). 799–806. 94 indexed citations

Cornely, Oliver A., David Helfgott, Amelia Langston, et al.. (2012). Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection. Antimicrobial Agents and Chemotherapy. 56(5). 2652–2658. 31 indexed citations

Cornely, Oliver A., Johan Maertens, Drew J. Winston, et al.. (2007). Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. New England Journal of Medicine. 356(4). 348–359. 1284 indexed citations breakdown →

Cornely, Oliver A., Johan Maertens, D. J. Winston, et al.. (2005). Posaconazole vs Standard Azole (FLU/ITRA) Therapy for Prophylaxis of Invasive Fungal Infections (IFIs) among High-Risk Neutropenic Patients: Results of a Randomized, Multicenter Trial.. Blood. 106(11). 1844–1844. 14 indexed citations

Poll, T. van der, et al.. (1996). Effects of anti-interleukin 6 on inflammatory responses during murine septic peritonitis. Innate Immunity. 3(6). 463–470. 2 indexed citations

Poll, Tom van der, et al.. (1996). Effects of anti-interleukin 6 on inflammatory responses during murine septic peritonitis. Journal of Endotoxin Research. 3(6). 463–470. 3 indexed citations

10.

Keogh, C V, Lyle L. Moldawer, David Helfgott, et al.. (1994). Role and effect of TNF- alpha in experimental visceral leishmaniasis.. The Journal of Immunology. 153(2). 768–775. 111 indexed citations

11.

Havell, Edward A., Lyle L. Moldawer, David Helfgott, P L Kilian, & Pravin B. Sehgal. (1992). Type I IL-1 receptor blockade exacerbates murine listeriosis. The Journal of Immunology. 148(5). 1486–1492. 121 indexed citations

12.

Helfgott, David, Stephen B. Tatter, Uma Santhanam, et al.. (1989). Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection.. The Journal of Immunology. 142(3). 948–953. 214 indexed citations

13.

Ray, Anuradha, Stephen B. Tatter, Uma Santhanam, et al.. (1989). Regulation of Expression of Interleukin‐6. Annals of the New York Academy of Sciences. 557(1). 353–362. 83 indexed citations

14.

Moldawer, Lyle L., Annabel Barber, C V Keogh, et al.. (1989). Interleukin‐1 and Interleukin‐6 Synergize to Increase Plasma Amyloid P and C3 Concentrations in the Mouse^a. Annals of the New York Academy of Sciences. 557(1). 528–531. 5 indexed citations

15.

Helfgott, David, et al.. (1989). Interferon‐β₂/Interleukin‐6 in Plasma and Body Fluids during Acute Bacterial Infection. Annals of the New York Academy of Sciences. 557(1). 562–563. 7 indexed citations

16.

Sehgal, Pravinkumar B., David Helfgott, Uma Santhanam, et al.. (1988). Regulation of the acute phase and immune responses in viral disease. Enhanced expression of the beta 2-interferon/hepatocyte-stimulating factor/interleukin 6 gene in virus-infected human fibroblasts.. The Journal of Experimental Medicine. 167(6). 1951–1956. 114 indexed citations

17.

May, L T, John Ghrayeb, Uma Santhanam, et al.. (1988). Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes.. Journal of Biological Chemistry. 263(16). 7760–7766. 216 indexed citations

18.

Helfgott, David, L T May, Zev Sthoeger, Igor Tamm, & Pravinkumar B. Sehgal. (1987). Bacterial lipopolysaccharide (endotoxin) enhances expression and secretion of beta 2 interferon by human fibroblasts.. The Journal of Experimental Medicine. 166(5). 1300–1309. 175 indexed citations

19.

Fenton, Wayne A., Adelle M. Hack, David Helfgott, & Leah Rosenberg. (1984). Biogenesis of the mitochondrial enzyme methylmalonyl-CoA mutase. Synthesis and processing of a precursor in a cell-free system and in cultured cells.. Journal of Biological Chemistry. 259(10). 6616–6621. 50 indexed citations

20.

Helfgott, David & Neville R. Kallenbach. (1979). Increased binding of ethidium bromide to polynucleotide duplexes containing mismatched bases. Nucleic Acids Research. 7(4). 1011–1018. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact